Aardvark Therapeutics
AARD · NASDAQ
$3.90+$0.16 (+4.28%)TodayMarket closed ·
Prev close $3.74
Who owns AARD
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 60.4% of AARD’s shares.
- Decheng Capital LLC17.9%
- Vickers Venture Partners9.4%
- Lee (Tien-Li)7.1%
- Lee (Jane Wu)6.7%
- Next 6 largest institutions19.3%
- All other shareholders39.6%
| Holder | Shares | % of shares |
|---|---|---|
| Decheng Capital LLC | 3.92M | 17.90% |
| Vickers Venture Partners | 2.05M | 9.37% |
| Lee (Tien-Li) | 1.55M | 7.09% |
| Lee (Jane Wu) | 1.47M | 6.74% |
| Citadel Advisors LLC | 1.28M | 5.86% |
| Laurion Capital Management LP | 1.03M | 4.73% |
| Vanguard Capital Management, LLC | 562.88K | 2.57% |
| AQR Capital Management, LLC | 480.25K | 2.19% |
| Sun (Nelson B.) | 466.25K | 2.13% |
| EcoR1 Capital, LLC | 396.19K | 1.81% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Vanguard Total Stock Market Index Fund | 408.67K | 1.87% |
| Vanguard Extended Market Index Fund | 140.39K | 0.64% |
| iShares Biotechnology ETF | 93.40K | 0.43% |
| Fidelity Extended Market Index Fund | 64.83K | 0.30% |
| iShares Micro-Cap ETF | 45.65K | 0.21% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders sold $394.96K (2 trades) of AARD on the open market, with no buys.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Zhang Zhongwei | Award | 127.06K | — |
| Sun Nelson | Sale | 62.00K | $321.18K |
| Sun Nelson | Sale | 14.75K | $73.78K |
| Chi Jeffrey | Award | 44.96K | — |
| Tong Victor Edward Jr | Award | 44.96K | — |
| Baynes Roy D. | Award | 44.96K | — |
| Graf Susan E | Award | 44.96K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 474.08K
- Days to cover
- 5.29
- % of shares outstanding
- 2.17%
- Average daily volume
- 89.63K
- Change since last report
- +11.6%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.